Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Comparing Corporate Presentations
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by canadapieton Jul 30, 2022 9:20am
127 Views
Post# 34862022

RE:RE:RE:RE:Comparing Corporate Presentations

RE:RE:RE:RE:Comparing Corporate Presentations
Indeed!!

And what about all the talking with potential partners from their strong position??????!!!
Lies...............

Nobody for now sees value in TH, not even managemnet itself at such ridiculous low shareprice!!! 
Shameful/Disgusting!!!


CreatingApe - (7/30/2022 8:16:55 AM)
RE:RE:RE:Comparing Corporate Presentations

Mr. spceo. I am a little baffled and frustrated by all this talk of patent issues with Egrifta as of late. I remember clearly many months ago you stating that they had a secured the patent for Egrifta for Nash out to 2044 or something. and that was one more worry we could take off the table. Which I took to heart. Can you explain to me where all these recent patent worries are coming from?? I remember clearly being told maybe a year or more ago now that they had secured new patents and the worry about generic competition was off the table for a very long time. For me this was very big and very encouraging news. What has changed? I would really appreciate an explanation because I now feel misled...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities